| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Harmony Biosciences Holdings, Inc
13G/A
Amendment 5
HRMY · 413197104
|
3.2% |
11/14/2025
Event 9/30/2025
|
|||
| Valor IV Pharma Holdings, LLC | 0% | ||||
| Valor Equity Partners IV L.P. | 1.3% | ||||
| Valor Equity Partners IV-A L.P. | 0% | ||||
| Valor Equity Partners IV-B L.P. | 0.7% | ||||
| Valor Equity Associates IV L.P. | 2.2% | ||||
| Valor Equity Capital IV LLC | 2.2% | ||||
| Valor Management L.P. | 2.2% | ||||
| Antonio J. Gracias | 3.2% | ||||
| Juan A. Sabater | 2.4% | ||||
|
Harmony Biosciences Holdings, Inc
13G/A
Amendment 4
HRMY · 413197104
|
11.7% |
2/12/2025
Event 12/31/2024
|
|||
| Valor IV Pharma Holdings, LLC | 11.6% | ||||
| Valor Equity Partners IV L.P. | 9.0% | ||||
| Valor Equity Partners IV-A L.P. | 0.5% | ||||
| Valor Equity Partners IV-B L.P. | 2.1% | ||||
| Valor Equity Associates IV L.P. | 11.6% | ||||
| Valor Equity Capital IV LLC | 11.6% | ||||
| Valor Management L.P. | 11.6% | ||||
| Antonio J. Gracias | 11.7% | ||||
| Juan A. Sabater | 11.6% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.